Positive Outlook for Alnylam Pharma Following FDA Approval of Amvuttra for TTR-CM

Analyst Ritu Baral of TD Cowen maintained a Buy rating on Alnylam Pharma (ALNY – Research Report), retaining the price target of $371.00.

Ritu Baral has given her Buy rating due to a combination of factors surrounding Alnylam Pharma’s recent FDA approval for Amvuttra in treating TTR-CM. The approval highlights the drug’s ability to reduce cardiovascular mortality, hospitalizations, and urgent heart failure visits, setting it apart from other treatments with its unique label language.
The absence of post-approval efficacy data commitments and significant safety concerns further strengthens the drug’s market position. Additionally, the promising clinical data, including statistically significant reductions in cardiovascular events and mortality, underpin the optimistic revenue projections and potential for peak sales. These elements collectively contribute to the positive outlook for Alnylam Pharma’s stock.

In another report released today, Barclays also maintained a Buy rating on the stock with a $329.00 price target.

Based on the recent corporate insider activity of 71 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ALNY in relation to earlier this year.